Sana Obtains License To Beam Therapeutics’ CRISPR Cas12b Gene Editing Technology
Sana Biotechnology Inc (NASDAQ:SANA) has secured non-exclusive commercial rights to Beam Therapeutics Inc’s (NASDAQ:BEAM) CRISPR Cas12b nuclease system for certain ex vivo engineered cell therapy…